Spatial Transcriptomics Highlights Inflammation in LP and DLE
Publication Title: Spatial Transcriptomics Reveals Differential Inflammatory Pathways in Discoid Lupus Erythematosus and Lichen Planus
Summary
- Question
- This study investigated the immune signaling pathways in two chronic autoimmune skin diseases, discoid lupus erythematosus (DLE) and lichen planus (LP), using spatial transcriptomics. The researchers aimed to identify differences in inflammatory pathways and immune responses between these conditions.
- Why it Matters
- DLE and LP are debilitating autoimmune skin disorders with significant morbidity and no FDA-approved treatments. Understanding their underlying immune mechanisms is crucial for developing targeted therapies. This research sheds light on disease-specific immune signatures, which may lead to improved treatments and better management of these conditions for patients.
- Methods
- The researchers used GeoMx Digital Spatial Profiling, a technology that analyzes RNA and protein in fixed tissue, to examine archived skin biopsies from 9 patients with DLE, 10 with LP, and 4 healthy controls. They profiled 1,868 genes across immune cells (CD45-positive) and keratinocytes (pan-cytokeratin-positive) to identify differences in gene expression and inflammatory pathways.
- Key Findings
The study revealed distinct immune signatures for DLE and LP. DLE exhibited heightened type 1 inflammation, driven by interferon (IFN) signaling, with increased expression of genes such as ISG15 and MX1. LP showed a mixed inflammatory response, with a notable type 2 immune signature characterized by genes like CCL18. Both diseases shared strong type 1 inflammation, but LP had significantly higher type 2 inflammation.
- Implications
These findings provide a deeper understanding of the immune mechanisms driving DLE and LP. The discovery of disease-specific pathways suggests potential targets for therapy. This research also highlights the importance of tailoring treatments to the unique immune profiles of each disease.
- Next Steps
- The authors recommend further investigation into cell-specific signaling and interactions between immune cells and skin cells in DLE and LP. Additionally, they suggest exploring targeted therapies that modulate the distinct inflammatory pathways identified in this study.
- Funding Information
- This research was supported by the Colton Center for Autoimmunity at Yale and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (awards K08AR080777 and T32AR001016). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Full Citation
Authors
Michal Antoni Kidacki, MD, PhD
First AuthorMatthew Vesely, MD, PhD
Last AuthorAssistant Professor of Dermatology